drugset / Trial / NCT06338826
Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses
RandomizedSequentialSingle-blindTreatment
Summary
The main objective of this study is to evaluate at 96 weeks the safety with respect to hepatitis B control of 2 treatment reduction strategies for patients with previously controlled HIV-HBV co-infection on continuous triple therapy
Timeline
- Start
- 2025-02-01
- Primary completion
- 2027-09-30
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darunavir | Small molecule | — | — |
| Subject | Dolutegravir | Other / unclassified | — | — |
| Subject | Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR) | Unknown | — | — |
| Subject | Lamivudine | Other / unclassified | 300 mg | — |
| Subject | Tenofovir disoproxil fumarate | Small molecule | 245 mg | — |
| Subject | emtricitabine | Other / unclassified | 200 mg | — |
| Subject | tenofovir alafenamide | Small molecule | 25 mg | — |
| Background | Atazanavir | Other / unclassified | — | — |
| Background | Cobicistat | Small molecule | — | — |
| Background | Doravirine | Small molecule | — | — |
| Background | Efavirenz | Other / unclassified | — | — |
| Background | Etravirine | Small molecule | — | — |
| Background | Raltegravir | Other / unclassified | — | — |
| Background | Rilpivirine | Small molecule | — | — |
| Background | Ritonavir | Other / unclassified | — | — |
| Background | bictegravir | Small molecule | — | — |
| Background | elvitegravir | Small molecule | — | — |